Background：Ipilimumab is a fully human IgG1 kappa antibody that binds to CTLA-4 cytotoxic T lymphocyte associated antigen 4, a molecule on T cells that is indicated for unresectable or metastatic melanoma. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells. The proposed mechanism of action is indirect, and may be through T-cell - mediated anti-tumor immune responses.
Alternative Names：BMS-734016, MDX-010, MDX-CTLA-4,
